|Videos|December 28, 2022

Dr. Magee on use of exogenous testosterone in patients with localized prostate cancer

Author(s)Urology Times staff

“Perspectives on testosterone therapy and its use as it pertains to prostate cancer have certainly progressed over [the] years,” Diana Magee, MD, MPH, MSc.

In this video, Diana Magee, MD, MPH, MSc, summarizes the 2022 Society of Urologic Oncology Annual Meeting presentation, “Use of exogenous testosterone in the setting of screening, active surveillance, and after treatment of localized disease.” Magee is a urologic oncology fellow at Fox Chase Cancer Center in Philadelphia, Pennsylvania.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

Nima Almassi, MD, highlights long-term data on bladder preservation in MIBC

ByNima Almassi, MD

August 13th 2026

Alan Bryce, MD, highlights key phase 3 advances in prostate cancer

ByAlan H. Bryce, MD

August 4th 2026

Kathryn Gessner, MD, PhD, on the challenges of selecting patients for bladder preservation

ByKate Gessner, MD, PhD

July 20th 2026

Jamie Michael, MD, discusses MRI and genomics in active surveillance

ByJamie Michael, MD

July 16th 2026

Ravi Munver, MD, highlights study of first- and second-generation Aquablation systems

ByRavi Munver, MD

July 14th 2026

Latest CME

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Trending on Urology Times

The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD

CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom

Kari Tikkinen, MD, PhD, discusses POISE-3 findings on tranexamic acid in urologic surgery

Rezūm shows greater 1-year BPH symptom relief vs pharmacotherapy

POTOMAC Subgroup Data: Cystectomy Risk and Rare Adverse Events in NMIBC